

Supporting Information

Low-Dose DOX–Polygodial Nanosystem Modulates CD47/CALR Axis for Safer Triple Negative Breast Cancer Treatment

Hadir M. Emar ¹, Rana A. Youness ², Tamer M. Manie ³, Anwar Abdelnaser ^{4,*}, and Nageh K.

Allam ^{1, 5,*}

¹ Nanotechnology Program, School of Sciences & Engineering, The American University in Cairo, New Cairo, 11835, Egypt

² Molecular Biology and Biochemistry Department, Molecular Genetics Research Team, Faculty of Biotechnology, German International University (GIU), New Administrative Capital, 11835, Egypt

³ Breast Surgery Department, National Cancer Institute, Faculty of Medicine, Cairo University, Cairo, Egypt

⁴ Institute of Global Health and Human Ecology, School of Sciences and Engineering, AUC - American University in Cairo, New Cairo, Egypt

⁵ Energy Materials Laboratory, Physics Department, School of Sciences & Engineering, The American University in Cairo, New Cairo, 11835, Egypt

Table S1: Detailed clinical records for each BC patient.



Patient No.	Age	Histology	Grade	Lymph-node metastasis	Molecular Subtype	ER	PR	HER-2	Tumor size (cm)	Ki-67	Menopause
Patient 1	55	IDC	II	Yes	Luminal B	Yes	Yes	Yes	1.2x3	High 28%	Post
Patient 2	68	IDC	II	Yes	Luminal B	Yes	Yes	No	1.8x1.9	High 24%	Post
Patient 3	34	IDC	II	Yes	TNBC	No	No	No	1.9x2	High 45%	Pre

Patient 4	52	IDC	II	No	Luminal B	Yes	Yes	Yes	1.8x2	High 24%	Post
Patient 5	34	IDC	II	Yes	TNBC	No	No	No	4.4x3.6	High 50%	Pre
Patient 6	26	IDC	II	No	TNBC	No	No	No	3.6x2.2	High 28%	Pre
Patient 7	41	IDC	III	Yes	TNBC	No	No	No	4.5x3.6	High 50%	Post
Patient 8	60	IDC	II	Yes	Luminal B	Yes	Yes	No	2.8x2.3	Low 10%	Post
Patient 9	55	IDC	II	No	Luminal B	Yes	Yes	Yes	2.5x1.6	High 35%	Pre
Patient 10	44	IDC	II	No	Luminal B	Yes	Yes	No	2x1.6	High 24%	Post
Patient 11	61	IDC	II	No	Luminal A	Yes	Yes	Yes	2.2x1.5	Low 12%	Post
Patient 12	57	IDC	II	No	HER-2	No	No	Yes	5x4	High 30%	Pre
Patient 13	32	IDC	III	Yes	TNBC	No	No	No	4.2x3.8 2.5x1.9	High 23%	Post
Patient 14	53	IDC	III	No	TNBC	No	No	No		High 24%	Post

Patient 15	57	IDC	II	No	HER-2	No	No	Yes	5x3.2	High 35%	Post
Patient 16	38	IDC	II	No	Luminal B	Yes	Yes	Yes	1.6x2.2	Low 12%	Pre
Patient 17	55	IDC	III	Yes	Luminal A	Yes	Yes	No	1.4x0.8	Low 12%	Post
Patient 18	71	IDC	II	Yes	Luminal A	Yes	Yes	No	2.2x1.7	High 30%	Post
Patient 19	49	IDC	III	No	Luminal B	Yes	Yes	Yes	3.9x2.5	High 35%	Post
Patient 20	42	IDC	II	No	Luminal B	Yes	Yes	Yes	2.8x3	High 35%	Pre
Patient 21	36	IDC	II	Yes	Luminal B	Yes	Yes	Yes	0.27x0.1 4	High 40%	Pre
Patient 22	20	IDC	II	Yes	TNBC	No	No	No	2.5x1.3	Low 12%	Pre
Patient 23	35	IDC	II	No	TNBC	No	No	No	1.1x2	High 50%	Pre

Patient 24	42	IDC	II	No	TNBC	No	No	No	4.5x6	High 45%	Pre
Patient 25	61	IDC	II	No	Luminal A	Yes	Yes	Yes	2x1.6	Low 12%	Post

(a)



(b)





Figure S1: Particle size distribution based on TEM images of nanoparticles at the 500 nm scale using ImageJ of: (a) Mean size of ≈ 188 for DOX+PG-loaded HA-CTN NPs, and (b) Mean size of ≈ 174 for plain HA-CTN NPs.